Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book introduces molecular imaging and Target Therapy in various cancers. The first part is the subjects and primary focused on the basics of nuclear physics, radiation dosimetry, nuclear medicine equipment and small animal imaging equipment. The second part is about the radiopharmaceutical and commonly used clinical radiopharmaceuticals, including positron emission imaging agent, single photon emission imaging agent, and radionuclide therapy agents as well as their radioactive preparation, quality control, and a brief clinical application were included. Also, this part introduces a number of new imaging agents which were potential value of clinical applications. In the third part, the clinical application of the conventional imaging agent 18F-FDG in different tumors and neurodegenerative diseases and 18F-Dopa imaging in the nervous system are discussed. Besides the clinical applications of 99mTc labeled radiopharmaceuticals in parathyroid disease, coronary heart disease, myocardial infarction, sentinel lymph node, metastatic bone tumors, liver and gallbladder disease in children are introduced. Finally, the applications of radionuclide 131I on treatments of Graves' disease and differentiated thyroid cancer and metastases are investigated respectively. This book is a useful reference for professionals engaged in nuclear medicine and clinical research, including clinical nuclear medicine physicians, nuclear medicine engineers and nuclear medicine pharmacists.

Oncology  . --- Nuclear medicine. --- Interventional radiology. --- Oncology. --- Nuclear Medicine. --- Interventional Radiology. --- Radiology, Interventional --- Medical radiology --- Therapeutics --- Atomic medicine --- Radioisotopes in medicine --- Radioactive tracers --- Radioactivity --- Tumors --- Physiological effect --- Interventional radiology .

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This comprehensive volume covers radiopharmaceuticals developed for pathway-directed systems in imaging and theranostic applications. We now are at the cutting edge of providing personalized treatment with increased use in oncology of these new radiopharmaceuticals. Trends in high-resolution instrumentation development, quality assurance systems and regulatory compliance for radiopharmaceuticals, clinical evaluation of radiopharmaceuticals, and benefits and pitfalls of the current clinical FDG PET are discussed. Radiopharmaceuticals are used for diagnosis of diseases of the central nervous and cardiovascular systems and for staging, restaging, and treatment planning for cancers. Nuclear biomarkers allow precise measurement of molecular pathways on a whole-body image upon administration of functional radiolabeled agents, and nuclear imaging agents have potential use in patient selection, pharmacokinetic, dosage-finding, and proof-of-concept studies. Nuclear imaging agents and hybrid instrumentation also provide sensitive and specific answers for differential responsiveness in therapeutic outcome. This book serves as a reference for moving the discovery and development of radiopharmaceuticals from the workbench to clinical applications. It thus benefits not only clinicians but also translational research scientists—molecular biologists, chemists, imaging scientists, pharmaceutical developers, physicists, and support staff.

Nuclear medicine. --- Oncology  . --- Nuclear Medicine. --- Oncology.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This comprehensive volume covers radiopharmaceuticals developed for pathway-directed systems in imaging and theranostic applications. We now are at the cutting edge of providing personalized treatment with increased use in oncology of these new radiopharmaceuticals. Trends in high-resolution instrumentation development, quality assurance systems and regulatory compliance for radiopharmaceuticals, clinical evaluation of radiopharmaceuticals, and benefits and pitfalls of the current clinical FDG PET are discussed. Radiopharmaceuticals are used for diagnosis of diseases of the central nervous and cardiovascular systems and for staging, restaging, and treatment planning for cancers. Nuclear biomarkers allow precise measurement of molecular pathways on a whole-body image upon administration of functional radiolabeled agents, and nuclear imaging agents have potential use in patient selection, pharmacokinetic, dosage-finding, and proof-of-concept studies. Nuclear imaging agents and hybrid instrumentation also provide sensitive and specific answers for differential responsiveness in therapeutic outcome. This book serves as a reference for moving the discovery and development of radiopharmaceuticals from the workbench to clinical applications. It thus benefits not only clinicians but also translational research scientists—molecular biologists, chemists, imaging scientists, pharmaceutical developers, physicists, and support staff.

Nuclear medicine. --- Oncology  . --- Nuclear Medicine. --- Oncology.